Miquel Vila-Perello

CEO at Splice Bio

Speaker

Dr. Miquel Vila-Perelló is the co-founder and Chief Executive Officer of SpliceBio, a genetic medicines company he has led since its inception in 2014 (formerly ProteoDesign). Under his leadership, SpliceBio has grown from an early-stage concept into a global clinical-stage biotechnology company, advancing multiple programs into development—including the lead program for Stargardt disease currently in the clinic—and securing over $200 million in funding from top-tier investors.
The company’s foundation and technology are rooted in Dr. Vila-Perelló’s pioneering research on protein splicing and engineering at Princeton University, where he served as a Research Scholar and managed the Protein Center in the Department of Chemistry. Prior to that, he spent six years at The Rockefeller University as a postdoctoral researcher, contributing to the development of innovative protein ligation technologies.

Dr. Vila-Perelló has dedicated the past two decades to advancing protein engineering for therapeutic development, both as a scientist and as a biotech executive. As CEO of SpliceBio, he has overseen the company’s scientific and corporate growth, from early research to clinical stage and international expansion. He is also the author of over 23 peer-reviewed publications and the inventor of multiple granted patents. Dr. Vila-Perelló holds a PhD in Chemistry from the University of Barcelona.